HD-tDCS for schizophrenia may offer a more targeted way to address symptoms that frequently persist despite medication. A new randomized study suggests that its effects may be measurable not only through clinical assessments, but also through changes in cortical inhibition.
Negative symptoms such as reduced motivation, limited emotional expression, social withdrawal, and diminished speech can substantially affect daily functioning. Antipsychotic medications remain central to schizophrenia treatment, but their strongest effects are generally seen in positive symptoms such as hallucinations and delusions.
That leaves a persistent therapeutic gap. Researchers are increasingly examining whether noninvasive brain stimulation can complement standard care by influencing circuits involved in motivation, cognition, and emotional processing.
A More Focused Form Of Brain Stimulation
Transcranial direct current stimulation uses a weak electrical current to alter the activity of targeted brain regions. High-definition tDCS, or HD-tDCS, applies that current through a more concentrated electrode arrangement, allowing researchers to create a more focal electric field than conventional tDCS.
In this study, investigators targeted the left dorsolateral prefrontal cortex, a region involved in executive function, emotional regulation, and broader prefrontal-limbic communication. Participants assigned to active treatment received 20 sessions of 1.5 mA anodal stimulation. The control group received sham stimulation under double-blind conditions.
The trial included 103 patients with schizophrenia, with 52 assigned to active HD-tDCS and 51 assigned to sham treatment. Researchers also evaluated 76 healthy participants during the initial neurophysiological phase.
How HD-tDCS For Schizophrenia Was Measured
The study combined clinical symptom ratings with transcranial magnetic stimulation and electroencephalography, known as TMS-EEG. This method applies magnetic pulses to the cortex while EEG records the brain’s immediate electrical responses.
Researchers focused on TMS-evoked potentials, including a response called the N100. This negative waveform appears approximately 100 milliseconds after stimulation and is commonly interpreted as an indicator of inhibitory cortical activity, particularly signaling associated with GABA-B receptors.
At baseline, patients with schizophrenia showed lower N100 amplitudes than healthy controls. Greater N100 disruption was also associated with more severe negative symptoms, supporting a relationship between impaired inhibitory processing and the clinical presentation of schizophrenia.
Clinical Improvement Accompanied N100 Normalization
Active HD-tDCS produced larger improvements than sham stimulation across negative symptoms, positive symptoms, and general psychopathology. The largest reported effect was observed in negative symptoms, with an effect size of d = -1.46.
Following active treatment, N100 responses moved toward the pattern observed in healthy participants. Importantly, the amount of N100 change was specifically associated with improvement in negative symptoms. It was not significantly related to changes in positive symptoms or general psychopathology.
This specificity strengthens the possibility that N100 normalization reflects a treatment-relevant process rather than a broad, nonspecific response to symptom improvement.
Restoring Balance Within Cortical Circuits
Healthy brain function depends on coordination between excitatory and inhibitory signaling. Excitatory glutamate pathways help activate neural circuits, while inhibitory GABA pathways regulate their timing, selectivity, and stability.
Schizophrenia has been associated with disturbances in this balance. If HD-tDCS strengthens inhibitory regulation within prefrontal circuits, it could improve the brain’s ability to organize information and coordinate activity across connected networks.
Exploratory analyses also identified increased source current density within limbic networks after active treatment, with possible associations between these changes and symptom improvement. However, those results did not remain significant after correction for multiple comparisons and should be considered preliminary.
A Biomarker-Informed Model Of Treatment Response
What distinguishes this study is its staged design. Investigators first identified a neurophysiological difference between patients and healthy controls, then tested whether treatment altered that same signal and whether the alteration tracked clinical improvement.
The findings do not establish N100 as a validated clinical biomarker. Replication, longer follow-up periods, and studies across more diverse patient populations will be required. It also remains unclear how durable the improvements are or which patients are most likely to respond.
Still, the results present a measurable pathway connecting targeted stimulation, cortical inhibition, and negative symptom change. If confirmed, N100 could eventually help researchers evaluate treatment engagement and refine stimulation strategies for schizophrenia.
HD-tDCS remains investigational in this setting, but this study moves the field closer to a mechanistically informed approach in which symptom improvement can be evaluated alongside objective changes in brain function.
Citations
Neurophysiological Signatures Of Negative Symptom Improvement Following High-Definition Transcranial Direct Current Stimulation In Schizophrenia, Biological Psychiatry, 2026.
The NIMH-MATRICS Consensus Statement On Negative Symptoms, Schizophrenia Bulletin, 2006.
Explore more at https://www.interventionalpsychiatry.org/
